Agent | Targets | Conditions and Stage | Phase | Primary endpoint(s) | Biomarker | Companies | ID numbera | Studystart |
---|---|---|---|---|---|---|---|---|
Immunotherapy | ||||||||
 Pembrolizumab | PD-1 | Advanced; Second-line | III | OS | / | Merck Sharp & Dohme Corp. | CTR20160696 | 2017 |
 Tislelizumab (BGB-A317) | PD-1 | Unresectable; First-line | III | OS/Safety | / | BeiGene. | NCT03412773 | 2017 |
 Toripalimab (JS001) | PD-1 | Complete resection; Adjuvant | II/III | RFS | / | TopAlliance Biosciences Inc. | NCT03859128 | 2019 |
 Camrelizumab (SHR-1210) | PD-1 | Advanced; Second-line | II | ORR/OS (6 M) | / | Jiangsu HengRui Medicine Co., Ltd. | NCT02989922 | 2016 |
 CAR-T cell | EpCAM | EpCAM positive | I/II | Toxicity | / | First Affiliated Hospital of Chengdu Medical College. | NCT03013712 | 2017 |
 Infusion of iNKT cells and CD8+T cells | Lysis tumor cells | Advanced | I/II | AEs/ORR | / | Shanghai Public Health Clinical Center. | NCT03093688 | 2017 |
 KN035 | PD-L1 | Advanced | I | DLTs/AEs/ORR | / | 3D Medicines (Sichuan) Co., Ltd.; Alphamab Co., Ltd. | NCT03101488 | 2017 |
 GLS-010 injection | PD-1 | Advanced | I | AEs/AA | PD-L1 | Harbin Gloria Pharmaceutical Co., Ltd. | CTR20170692 | 2017 |
 iNKT cells | Lysis tumor cells | Relapsed, advanced | I | AEs | / | Beijing YouAn Hospital. | NCT03175679 | 2017 |
 ET1402L1-CAR-T cells | AFP | AFP+, advanced | I | DLT/Toxicity | AFP | Aeon Therapeutics (Shanghai) Co., Ltd. | NCT03349255 | 2017 |
 GPC3-T2-CAR-T cells | GPC3 | GPC3+ | I | DLT | / | Second Affiliated Hospital of Guangzhou Medical University. | NCT03198546 | 2017 |
Anti-angiogenesis | ||||||||
 Donafenib | VEGFR, PDGFR, RAF | Advanced; First-line | III | OS | / | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | NCT02645981 | 2016 |
 Lenvatinib (E7080) | VEGFR1–3, FGFR1–4, PDGFR α, RET, and KIT | Unresectable; First-line | III | OS | / | Eisai Co., Ltd. | CTR20131648 | 2014 |
 Muparfostat (PI-88) | FGF1–2, VEGF | Resected; Adjuvant | III | DFS | / | Medigen Biotechnology Corp. | CTR20131019 | 2015 |
 Brivanib (ZL-2301) | VEGFR, FGFR | Advanced; Second-line | II | DCR (3 M) | / | Zai Lab Pharmaceutical (Shanghai) Co., Ltd. | CTR20170216 | 2017 |
 Lucitanib (AL3810) | FGFR1–2, VEGFR1–3 | Advanced or metastatic | Ib | AE | / | Shanghai Institute of Materia Medica; Academia Sinica. | CTR20160271 | 2016 |
 Metatinib Trometamol tablets | MET/VEGFR2 | Advanced or metastatic | Ib | AE | MET | Simcere Pharmaceutical Co., Ltd. | CTR20150743 | 2015 |
 Chiauranib | VEGFR, PDGFRa, KIT, Aurora B and CSF-1R | Advanced | I | PFR (16 W) | / | Chipscreen Biosciences, Ltd. | NCT03245190 | 2018 |
Cell cycle inhibitors and Anti-proliferation | ||||||||
 Erdafitinib (JNJ-42756493) | FGFR | Advanced; FGF19 amplification | I/II | RP2D/ORR | / | Janssen Research & Development, LLC. | NCT02421185 | 2015 |
 ATG-008 (CC-223) | mTORC1/2 | HBV+, Advanced; Second-line | II | PK/AEs/ORR | TORC1/2 and others | Antengene Corporation. | NCT03591965 | 2018 |
Combination therapy | ||||||||
 PD-1 Antibody Plus Lenvatinib | PD-1 + VEGFR1–3, FGFR1–4, PDGFR α, RET, and KIT | Advanced | III | OS | / | Sun Yat-sen University. | NCT03744247 | 2019 |
 HLX10 plus HLX04 | PD-1+ VEGF | Locally Advanced or Metastatic; First-line | III | OS/PFS | / | Shanghai Henlius Biotech. | NCT04465734 | 2020 |
 Durvalumab plus Tremelimumab | PD-L1 + CTLA-4 | Unresectable; First-line | III | OS/AE | / | MedImmune LLC. | CTR20180607 | 2018 |
 SHR-1210 plus FOLFOX4 | PD-1 + DNA Synthesis | Advanced; First-line | III | OS | / | Jiangsu HengRui Medicine Co., Ltd. | NCT03605706 | 2018 |
 SHR-1210 plus Apatinib | PD-1 + VEGFR-2 | Advanced; First-line | III | OS/PFS | / | Shanghai HengRui Medicine Co., Ltd. | CTR20182528 | 2019 |
 Sintilimab plus IBI305 | PD-1 + VEGF | Advanced; First-line | II/III | OS/ORR | / | Innovent Biologics (Suzhou) Co. Ltd. | NCT03794440 | 2019 |
 AK105 plus Anlotinib or AK105 plus Bevacizumab | PD-1 + VEGFR, PDGFR, FGFR, KIT or PD-1 + VEGFA | Unresectable; First-line | Ib/II | ORR | / | Akeso (Guangdong) Biopharma, Inc. | CTR20182026 | 2018 |
 PD-1 mAb plus PolyIC | PD-1 + TLR3 | Unresectable | II | ORR | AFP | Second Affiliated Hospital, School of Medicine, Zhejiang University. | NCT03732547 | 2018 |
 PHY906 plus Sorafenib | Chinese herbal formulation+VEGFRs, KIT, PDGFRs, and RAF | Advanced | I | RP2D | / | City of Hope Medical Center. | NCT01666756 | 2013 |
Traditional Chinese medicine | ||||||||
 Xihuang Capsules | / | Resected | IV | recurrence rate | / | Shuqun Cheng, Eastern Hepatobiliary Surgery Hospital. | NCT02399033 | 2015 |
 Icaritin | ERa36 | Advanced; HBV-Related | III | OS | PD-L1, hnRNPAB1, IL-6 and others | Beijing Shenogen Biomedical Co., Ltd. | NCT03236636 | 2017 |
 Icaritin | ERa36 | PD-L1+, advanced | III | OS | PD-L1, hnRNPAB1, IL-6 and others | Beijing Shenogen Biomedical Co., Ltd. | NCT03236649 | 2017 |
 Ursolic acid nanoliposomes injection | IKKβ | Advanced; | I | ORR | / | Wuhan Liyuanheng Pharmaceutical Co., Ltd. | CTR20140395 | 2016 |
 Chlorogenic acid | cell cycle | Advanced; | I | DLT/MTD | / | Sichuan Jiuzhang Biotech Co., Ltd. | CTR20130586 | 2014 |
 Jiu-wei-zhen-xiao Granule | / | Advanced; Unresectable | I | PFS | / | Zhong Wang, China Academy of Chinese Medical Sciences. | NCT03851471 | 2019 |
Other mechanisms | ||||||||
 K-001 (Marine biological products) | anti-inflammation, anti-angiogenesis | Advanced | III | OS | AFP | Beijing Huashi Tianfu Biomedical Technology Co., Ltd. | CTR20132910 | 2014 |
 IFN-alpha | pro-apoptosis, anti-proliferation | Resected; low miR-26 expression | III | DFS | miR-26 | Fudan University. | NCT01681446 | 2012 |
 Galunisertib (LY2157299) | TGF-β | Advanced; First-line | II | OS | / | Eli Lilly and Company. | CTR20150343 | 2015 |
 Boanmycin Hydrochloride for Injection | cytotoxic agent | / | II | ORR | / | DIKANG Pharmaceutical. | CTR20140308 | 2015 |
 PT-112 | pro-apoptosis, immunogenic cell death inducer | Advanced | I/II | AEs/DLTs/DCR | / | SciClone Pharmaceuticals. | NCT03439761 | 2018 |
 Hemay102 | cytotoxic agent | Advanced; | I | AE | / | Hainan Hailing Chemipharma Corporation Limited. | CTR20181497 | 2018 |
 ZSP1241 | / | Advanced | I | MTD/DLT/AEs | / | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | NCT03734926 | 2018 |
 CGX1321 | WNT | Advanced | I | AEs | / | Curegenix Inc. | NCT03507998 | 2017 |